Clinical Trial Update: Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin in adults with chronic obstructive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Danirixin (danirixin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2017-05-18